- •Foreword
- •Preface
- •Contents
- •1: Facial Anatomy
- •1.1 Introduction
- •1.2 Facial Skeleton
- •1.5 Retaining Ligaments
- •1.6 Mimetic Muscles
- •1.7 Deep Plane Including the Deep Fat Compartments
- •1.8 Facial Nerve
- •1.9 Sensory Nerves
- •1.10 Arteries of the Face
- •References
- •2: Facial Proportions
- •2.1 Introduction
- •2.2 Surface Markings
- •2.3 Proportions
- •2.4 The Golden Ratio
- •2.5 Planes and Angles
- •2.6 Conclusions
- •References
- •3.1 Introduction
- •3.2 Details of Zones
- •3.2.1 Zone 1
- •3.2.2 Zone 2
- •3.2.3 Zone 3
- •3.2.4 Zone 4
- •3.2.5 Zone 5
- •3.2.6 Zone 6
- •3.2.7 Zone 7
- •3.3 Conclusions
- •References
- •4: Muscles Used in Facial Expression
- •4.1 Introduction
- •4.2 Discussion
- •References
- •5.1 Introduction
- •5.2 Studies and Technique
- •5.3 Results
- •5.4 Discussion
- •5.4.1 SMAS and SMAFS: Concept and Variations
- •5.4.1.1 Sleep Lines
- •5.4.1.2 Membranous SMAFS
- •5.4.1.3 Fatty SMAFS
- •5.4.1.4 Flaccid SMAFS
- •5.4.1.5 Mixed SMAFS
- •5.4.1.7 Fleshy SMAFS
- •5.4.1.8 Fibrous SMAFS
- •5.4.1.9 SMAFS Sleep Lines Correction
- •5.5 Conclusions
- •References
- •6.1 Introduction
- •6.2 Surgical Facility
- •6.3 Ancillary Personnel
- •6.4 Preoperative Evaluation
- •6.4.1 Preoperative Risk Assessment
- •6.4.3 Cardiac Disease
- •6.4.4 Obesity
- •6.4.5 Hypertension
- •6.4.6 Diabetes Mellitus
- •6.4.7 Pulmonary Disease
- •6.4.8 Obstructive Sleep Apnea
- •6.4.9 Malignant Hyperthermia Susceptibility
- •6.5 Selections and Delivery of Anesthesia
- •6.5.1 Local Anesthesia
- •6.5.3 Regional Anesthesia
- •6.5.4 General Anesthesia
- •6.5.5 Preoperative Preparation
- •6.5.6 Perioperative Monitoring
- •6.5.7 Fluid Replacement
- •6.5.8 Recovery and Discharge
- •References
- •Recommended Reading
- •7.1 Introduction
- •7.3 Other Considerations
- •7.4 Assessing Level of Sedation
- •7.5 Agents Used in Sedation
- •7.5.1 Propofol
- •7.5.2 Benzodiazepines
- •7.5.3 Clonidine and Dexmedetomidine
- •7.5.4 Ketamine
- •7.5.5 Opioids
- •7.5.6 Acetaminophen
- •7.5.8 Other Agents
- •7.6 Devices Used in the Delivery of Sedation
- •7.7 Postoperative Nausea and Vomiting (PONV)
- •7.7.1 Risk Factors
- •7.8 Techniques of Sedation
- •7.9 Conclusions
- •References
- •8: Preoperative and Postoperative Plan
- •8.1 Plan for Facelift Surgery
- •8.2 Facelift Preoperative Instructions
- •References
- •9: Facial Imaging
- •9.1 Introduction
- •9.2 The Camera
- •Practical Tips
- •9.3 Resolution
- •Practical Tips on Resolution
- •9.4 Lighting
- •Practical Tips
- •9.5 Background
- •Practical Tips
- •9.6 Advertising and Ethics
- •9.7 Before and After Photos
- •9.8 Consent
- •Practical Tips for Consent for Photography
- •9.9 Special Problems with Consent
- •9.10 Radiology
- •9.10.1 Computed Tomography (CT)
- •9.10.2 Magnetic Resonance Imaging (MRI)
- •10.1 Introduction
- •10.2 Skin Aging
- •10.3 Techniques
- •10.3.1 Skin Care Program
- •10.3.1.1 Tretinoin
- •10.3.1.2 Skin Cleansers
- •10.3.1.3 Sun Protection
- •10.3.1.4 Light Chemical Peel or “Friendly Peel”
- •10.3.1.5 Microdermabrasion
- •10.3.1.6 Carboxytherapy
- •10.4 Complications
- •10.5 Discussion
- •10.6 Conclusions
- •References
- •11: What Is Human Beauty?
- •11.1 Introduction
- •11.2 Beauty
- •11.2.1 What Is Human Beauty? What Do the Books Say? Dictionaries? Philosophers?
- •11.2.2 Konrad Lorenz’s Theory
- •11.3 Conclusion
- •11.4 Summary
- •12: Body Dysmorphic Disorder
- •12.2 Symptoms
- •12.3 Consequences of BDD
- •12.4 Associated Disorders
- •12.5 Treatment
- •12.6 Discussion
- •12.7 Conclusions
- •References
- •13: Hair Transplantation
- •13.1 Introduction
- •13.3 Modern Hair Transplantation and Terminology
- •13.4 Nonsurgical Treatment Options
- •13.4.1 Medications
- •13.5 Nonmedical Treatments
- •13.6 Preoperative Consultation
- •13.7 Female Considerations
- •13.8 Preoperative Instructions
- •13.9 Surgical Planning
- •13.9.1 Men with MPB
- •13.9.2 The Crown
- •13.9.3 Females
- •13.9.4 Selection of Donor Area Site and Size
- •13.9.5 Estimating Size of Donor Strip
- •13.10 Anesthesia
- •13.11 Removal of Donor Strip
- •13.12 Follicular Unit Extraction
- •13.12.1 Indications for FUE
- •13.12.2 Advantages of FUE
- •13.12.3 Disadvantages of FUE
- •13.13 Graft Preparation
- •13.14 Recipient Site Creation
- •13.15 Graft Orientation: CAG or SAG
- •13.16 Instruments (Table 13.3)
- •13.17 Re-creating a Natural Hairline
- •13.18 Planting Recipient Grafts
- •13.19 The Vertex Region
- •13.20 Postoperative Care
- •13.21 Complications
- •13.21.1 Surgical Complications/Side Effects
- •13.21.2 Cosmetic/Esthetic Complications
- •13.22 Examples of Applications for Hair Transplants
- •13.22.1 Male Pattern Baldness
- •13.22.2 Female Pattern Hair Loss
- •13.22.3 Transplants After Rhytidectomy
- •13.22.4 Transplants After Burns
- •13.23 Non-scalp Areas
- •13.24 Transgendered Patients
- •13.25 Conclusions
- •References
- •14: Ablative Laser Facial Resurfacing
- •14.1 Introduction
- •14.2 Technique
- •14.2.1 Preoperative Preparation
- •14.2.2 Carbon Dioxide Laser
- •14.2.3 Erbium Laser
- •14.2.4 Postoperative Care
- •14.3 Complications
- •14.4 Discussion
- •14.5 Conclusions
- •References
- •15: Photorejuvenation
- •15.1 Introduction
- •15.2 Technique
- •15.3 Complications
- •15.4 Discussion
- •15.5 Conclusions
- •References
- •16.1 Introduction
- •16.2 Skin Anatomy
- •16.3 Technique
- •16.3.1 Patient Selection
- •16.3.2 Pretreatment
- •16.3.3 Technique
- •16.4 Alpha Hydroxy Acids
- •16.5 Salicylic Acid
- •16.6 Jessner’s Peel
- •16.6.1 Medium Depth Peels
- •16.7 Trichloroacetic Acid
- •16.8 Adjunctive Measures
- •16.9 Postoperative Care
- •16.10 Complications
- •16.11 Discussion
- •16.12 Conclusions
- •References
- •17: Deep Phenol Chemical Peels
- •17.1 Introduction
- •17.2 Patient Selection
- •17.3 Technique
- •17.4 Complications
- •17.5 Conclusions
- •References
- •18: Chemical Blepharoplasty
- •18.1 Introduction
- •18.2 Skin Preparation
- •18.3 Skin Evaluation and Chemical Agent Selection
- •18.4 Anesthesia and Sedation
- •18.5 Details of the Procedure
- •18.6 The Postoperative Period
- •18.7 Complications
- •18.7.1 Ectropion
- •18.7.4 Web Formation
- •18.7.5 Eyelid Skin Infection
- •18.8 Discussion
- •18.9 Conclusion
- •References
- •19: Facial Implants
- •19.1 Introduction
- •19.2 Technique
- •19.2.1 Midface Implants
- •19.2.2 Mandibular Implants
- •19.3 Complications
- •19.4 Discussion
- •19.5 Conclusions
- •References
- •20: Injectable Facial Fillers
- •20.1 Introduction
- •20.2 Historical Background
- •20.3 Available Facial Fillers
- •20.3.1 Autologous Fat
- •20.3.2 Collagen
- •20.3.3 Hyaluronic Acids (HAs)
- •20.3.4 Synthetic Polymers
- •20.4 Technical Considerations
- •20.5 Injection Techniques
- •20.6 Post-procedural Considerations
- •20.7 Facial Filler Complications
- •20.8 Conclusions
- •References
- •Recommended Reading
- •21: Botulinum Toxin for Facial Rejuvenation
- •21.1 Introduction
- •21.2 History
- •21.3 Chemical Overview
- •21.5 Onset and Duration of Paralysis
- •21.10 Locations of Treatment
- •21.10.1 Upper Face
- •21.10.2 Midface
- •21.10.3 Lower Face
- •21.11 New Frontiers for Botulinum Toxin in Facial Rejuvenation
- •21.12 Contraindications
- •21.13 Avoidance of Potential Pitfalls
- •21.15 Conclusions
- •References
- •22: History of Fat Transfer
- •22.1 Introduction
- •22.2 History
- •References
- •23.1 Introduction
- •23.2 Relevant Anatomy and Pathophysiology
- •23.3 Clinical Applications
- •23.3.1 Harvesting the Fat
- •23.3.2 Preparation
- •23.4 Applications and Injection Techniques
- •23.4.1 Injection Methods
- •23.5 Complications
- •References
- •24.1 Introduction
- •24.2 Patient Assessment
- •24.4 Anatomy
- •24.5 Liposuction
- •24.6 Tumescent Anesthesia
- •24.7 Liposuction Technique
- •24.8 Summary of Critical Points for Successful Liposuction
- •24.9 Chin Implantation
- •24.10 Submentoplasty
- •24.10.1 Submentoplasty Technique
- •24.11 Dealing with the Visible Submandibular Gland
- •24.12 Complications
- •24.12.1 Over-resection of Fat
- •24.12.2 Sialocele
- •24.12.3 Nerve Injury
- •24.12.4 Seroma
- •24.12.5 Skin Redundancy
- •24.12.6 Chronic Pain
- •24.12.8 Infection
- •24.12.9 Bleeding and Hematomas
- •24.12.10 Skin Slough
- •24.13 Conclusions
- •References
- •Submental Liposuction
- •26: Vaser UAL for the Heavy Face
- •26.1 Introduction
- •26.2 Technologies
- •26.3 Technique
- •26.4 Complications
- •27: Suture Facelift Techniques
- •27.1 Introduction
- •27.2 Concept
- •27.3 Patient Selection
- •27.4 Suture Types and Materials
- •27.4.1 Barbed Sutures
- •27.4.1.2 Anchored Bidirectional Barbed Sutures
- •27.4.1.3 Unidirectional Barbed Sutures
- •27.4.2 Non-barbed Sutures
- •27.4.2.1 Nonabsorbable Non-barbed Sutures
- •27.4.2.2 Absorbable Non-barbed Sutures
- •Upper Face
- •Midface
- •Lower Face
- •Neck
- •27.4.3 Coned Sutures
- •27.4.3.1 Midface
- •27.4.3.2 Neck
- •27.5 Postoperative Care
- •27.6 Complications
- •27.7 Conclusions
- •References
- •28: Bio-Lifting and Bio-Resurfacing
- •28.1 Introduction
- •28.2 Patient Desires
- •28.3 Aging of the Face
- •28.4 T3 Bioresurfacing
- •28.4.2 Young-Peel Method
- •28.4.2.2 Transdermal Introduction of Substances (Trans Peel)
- •28.4.3 Photodynamic Treatment
- •28.6 Biolifting
- •28.6.1 Method
- •28.6.1.2 Middle Layer
- •28.6.1.3 Deep Layer
- •28.6.1.4 Threads of Support
- •28.7 Endo Light Lift
- •28.8 Biodermogenesi™
- •28.9 Bio-Lifting: Protocol of Treatment
- •28.10 Conclusions
- •References
- •29: Standard Facelifting
- •29.1 Introduction
- •29.2 Technique
- •29.3 Postoperative Care
- •29.4 Complications
- •29.4.1 Hematoma
- •29.4.2 Nerve Injury
- •29.4.3 Infection
- •29.4.4 Skin Flap Necrosis
- •29.4.5 Hypertrophic Scarring
- •29.4.7 Parotid Gland Pseudocyst
- •29.5 Discussion
- •29.6 Conclusions
- •References
- •30.1 Introduction
- •30.4 Role of the Retaining Ligaments in Aging Face
- •30.5 Role of the Retaining Ligaments on Facelift
- •30.7 Presurgical Planning of Facelift
- •30.8 Facelift Procedure with Release and Suspension of the Retaining Ligaments and SMAS
- •30.8.1 Design of Skin Incision
- •30.8.2 Dissection
- •30.8.3 Liposuction
- •30.8.4 Treatment of Crow’s Feet and Sagging Lower Eyelid
- •30.8.5 Suspension
- •30.9 Clinical Cases
- •30.9.1 Case 1
- •30.9.2 Case 2
- •References
- •31.1 Introduction
- •31.2 Consultation
- •31.3.2 Photography
- •31.3.4 Preoperative Preparation on the Operating Table
- •31.3.5 Anesthesia: Intravenous Sedation
- •31.3.6 Nerve Mapping
- •31.3.8 Instrumentation
- •31.4 Procedure
- •31.5 The SMAS
- •31.6 Dressings
- •31.7 Results
- •References
- •32.1 Introduction
- •32.2 Technique
- •32.3 Complications
- •32.4 Discussion
- •32.5 Conclusions
- •References
- •33.1 Introduction
- •33.3.1 Marking
- •33.3.2 Anesthesia
- •33.4.1 Dressings
- •33.6 Disadvantages
- •References
- •34.1 Introduction
- •34.2 Strategy and Selection of SMAS Flap
- •34.3 SMAS Flap Study
- •34.4 Discussion
- •34.5 Conclusions
- •References
- •35.1 Introduction
- •35.2 Anatomic Considerations
- •35.2.1 The Facial Nerve
- •35.2.2 The SMAS Layer
- •35.3 Indications
- •35.4 Technique
- •35.5 Discussion
- •35.6 Complications
- •35.6.1 Hematoma
- •35.6.2 Nerve Injury
- •35.7 Conclusions
- •References
- •Recommended Reading
- •36.1 Introduction
- •36.2 Surgical and Functional Anatomy of the Face
- •36.2.1 Parotidomasseteric Fascia
- •36.2.2 Temporal Fascia
- •36.2.3 Deep Cervical Fascia
- •36.2.4 Malar: Buccal Fat Pad
- •36.2.5 Facial Mimetic Muscles
- •36.2.6 Facial Nerve
- •36.2.7 Retaining Ligaments
- •36.3 Anatomicohistologic Study of the Retaining Ligaments of the Face
- •36.3.1 Zygomatic Cutaneous Ligament (McGregor’s Patch)
- •36.3.2 Preauricular Parotid Cutaneous Ligament
- •36.3.3 Parotidomasseteric Cutaneous Ligament
- •36.3.4 Platysma Cutaneous Ligament
- •36.3.5 Mandibular Ligament
- •36.4 Aging Changes in the Face
- •36.5 Facelift and Historical Development of Retaining Ligaments of the Face
- •36.6 Retaining Ligament Correction and SMAS Plication in Facelift
- •36.6.1 Preparations for Surgery and Skin Marking
- •36.6.2 Surgical Technique
- •36.7 Postoperative Care and Complications
- •References
- •37.1 Introduction
- •37.2 Technique
- •37.3 Conclusions
- •References
- •38.1 Introduction
- •38.2 Preoperative Evaluation
- •38.3 Preoperative Markings
- •38.4 Anesthesia
- •38.5 Deep Plane Technique
- •38.6 Postoperative Care
- •38.7 Complications
- •38.8 Discussion
- •Recommended Reading
- •39: Subperiosteal Face-Lift
- •39.1 Introduction
- •39.2 Technique
- •39.2.1 Preoperative Evaluation
- •39.2.2 Surgical Technique
- •39.3 Complications
- •39.4 Discussion
- •39.5 Conclusions
- •References
- •40.1 Introduction
- •40.2 Limited Flap Rhytidectomy Procedures
- •40.3 Extended Flap Rhytidectomy Procedures
- •40.4 Deep-Plane Rhytidectomy
- •40.5 Adjuvant Procedures
- •References
- •41.1 Introduction
- •41.2 Pathomechanics
- •41.3 Preoperative Evaluation
- •41.3.1 Rhytidectomy in the Postbariatric Patient
- •41.4 Postoperative Care and Complications
- •41.5 Conclusions
- •References
- •42: Complications of Facelift Surgery
- •42.1 Introduction
- •42.2 Complications
- •42.2.1 Asymmetry
- •42.2.2 Bleeding
- •42.2.3 Dehiscence
- •42.2.5 Ear Deformities
- •42.2.6 Edema
- •42.2.7 Hair Loss
- •42.2.8 Hematoma
- •42.2.9 Infection
- •42.2.10 Irregularities
- •42.2.11 Necrosis
- •42.2.12 Neurological
- •42.2.13 Pain
- •42.2.14 Pigmentation Changes
- •42.2.15 Salivary Fistula
- •42.2.16 Scar
- •42.2.17 Seroma
- •References
- •43.1 Introduction
- •43.2 Historical Review
- •43.3 Anatomic Guidelines
- •43.4 The Eyebrow and Forehead as an Aesthetic Unit
- •43.5 Position of the Eyebrows
- •43.6 General Indications
- •43.7.1 Frontal Ptosis Degree
- •43.7.2 Depth of the Skin Furrows
- •43.7.3 Asymmetries
- •43.7.4 Frontal Redundant Skin
- •43.8 What Fixing Approaches and Techniques Do We Use?
- •43.8.1 Coronal
- •43.8.2 Pretrichial/Trichial
- •43.8.3 “Half Frontal”
- •43.8.4 Direct Eyebrow Lift
- •43.8.5 Endoscopic
- •43.9 Complications
- •43.10 Discussion
- •43.11 Conclusions
- •References
- •44: Endoscopic Forehead Lift
- •44.1 Forehead Aging Process
- •44.2 Indications
- •44.3 Alternative Methods
- •44.4 Anatomy
- •44.5 Endoscopic Forehead Lift Surgery: Rationale
- •44.6 Technique
- •44.6.1 Instruments
- •44.6.2 Anesthesia
- •44.6.3 Delimitation of the Working Areas
- •44.6.4 Skin Incisions
- •44.6.5 Subaponeurotic Supraperiosteal Dissection
- •44.6.6 Subperiosteal Dissection
- •44.6.7 Interfascial Dissection
- •44.6.8 Communication Between the Two Pockets
- •44.6.9 Endoscope Placement and Use
- •44.6.10 Periosteal and Muscular Sectioning
- •44.6.11 Fixation Suture Placement
- •44.6.12 Closure
- •44.6.13 Postoperative Follow-Up
- •44.7 Complications
- •44.8 Discussion
- •References
- •45.1 Introduction
- •45.2 History
- •45.3 Forehead Anatomy
- •45.5 Nonsurgical Techniques in Forehead Rejuvenation
- •45.6.1 Autogenous Fat Injection
- •45.6.2 Moisturizing Graft
- •45.6.3 Open Frontal Lift
- •45.6.4 Periorbital Approach
- •45.6.6 Forehead Endoscopic Rejuvenation
- •45.7 Complications
- •45.8 Conclusions
- •References
- •46.1 Introduction
- •46.2 Patient Marking
- •46.3 Surgical Procedure
- •46.4 Complications
- •46.5 Discussion
- •46.6 Conclusions
- •References
- •47: Endobrow Lift
- •47.1 Introduction
- •47.2 Anatomy
- •47.3 Endobrow Lift
- •47.3.1 Objectives of a Brow Lift
- •47.3.2 Preoperative Counseling
- •47.3.3 Learning Curve
- •47.3.5 Surgical and Nonsurgical Treatments of Forehead Rejuvenation
- •47.3.6 Direct Operations to the Brow
- •47.3.7 Endoscopic Brow Lift
- •47.3.8 Risks
- •47.4 Variations of Forehead and Brow Lift
- •47.5 Transpalpebral Corrugator Resection
- •47.6 Coronal Incision
- •47.7 Fat Grafting
- •47.8 Suspension and Suture Techniques
- •47.8.1 Thread Lift Guide
- •47.8.2 Thread Lift Risks
- •47.9 Botox (Chemodenervation with Botulinum Toxin)
- •47.10 Endobrow
- •47.10.1 Screw Placement
- •47.10.2 Possible Complications
- •References
- •48: Minimally Invasive Midface Lift
- •48.1 Introduction
- •48.2 Surgical Goals
- •48.3 Indications and Contraindications
- •48.4 Surgical Technique
- •48.4.1 Preoperative Markings
- •48.4.2 Anesthesia
- •48.4.5 Anchoring the Suture to the Deep Temporalis Fascia
- •48.5 Complications
- •48.6 Conclusions
- •Recommended Reading
- •49: Upper Eyelid Blepharoplasty
- •49.1 Introduction
- •49.2 Periorbital Aging
- •49.3 Anatomic Considerations
- •49.4 Musculature
- •49.5 Orbital Septum
- •49.6 Levator Palpebrae Superioris
- •49.7 Orbital Fat
- •49.8 Preoperative Evaluation
- •49.9 Ocular Assessment
- •49.10 Operative Procedure
- •49.11 Upper Eyelid Blepharoplasty Approach
- •49.12 Preparation
- •49.13 Postoperative Care
- •49.14 Complementary Treatments
- •49.14.1 Restoration of Infrabrow and Lateral Brow Volume
- •49.14.2 Injectable Fillers
- •49.14.3 Structural Fat Grafting of the Infrabrow Region
- •49.15 Complications
- •49.15.1 Hematomas
- •49.15.2 Blindness
- •49.15.3 Epiphora
- •49.15.4 Suture Line Complications
- •49.15.5 Wound Healing Complications
- •49.15.6 Ocular Injury
- •49.15.7 Contour Irregularities
- •References
- •50: Lower Eyelid Blepharoplasty
- •50.1 Introduction
- •50.2 Periorbital Aging
- •50.3 Anatomic Considerations
- •50.3.1 Lamellae
- •50.3.2 Musculature
- •50.3.3 Orbital Fat
- •50.3.4 Infraorbital and Midface Anatomy
- •50.4 Preoperative Evaluation
- •50.4.1 Ocular Assessment
- •50.4.3 Assessment of Tear Trough or Nasojugal Deformity
- •50.5 Operative Procedure
- •50.5.1 Technique
- •50.5.1.1 Transconjunctival Approach
- •Preparation
- •Postoperative Care
- •50.5.1.2 Skin–Muscle Flap Approach
- •Preparation
- •Incision
- •Fat Removal
- •Closure
- •Postoperative Care
- •50.6 Complementary Treatments with Restoration of Infraorbital Volume
- •50.6.1 Injectable Fillers
- •50.6.2 Orbital Fat Repositioning
- •50.6.3 Suborbicularis Oculi Fat Lift
- •50.7 Structural Fat Grafting of the Infraorbital Region
- •50.8 Complications
- •50.8.1 Ectropion
- •50.8.2 Hematomas
- •50.8.3 Blindness
- •50.8.4 Epiphora
- •50.8.5 Suture Line Complications
- •50.8.6 Wound Healing Complications
- •50.8.7 Skin Discoloration
- •50.8.8 Ocular Injury
- •50.8.9 Contour Irregularities
- •References
- •51: Upper Blepharoplasty of the Asian Eyelid
- •51.1 Introduction
- •51.2 Instrument List
- •51.3 Operative Technique
- •51.4 Postoperative Care
- •Reference
- •52: Medial and Lateral Epicanthoplasty
- •52.1 Introduction
- •52.3 Technique
- •52.3.1 Medial Epicanthoplasty
- •52.3.1.1 Elliptical excision: Von Ammon, Arlt, Hiraga, and Watanabe methods
- •52.3.1.2 Z-Plasty Method
- •52.3.2 Lateral Epicanthoplasty
- •52.4 Complications
- •52.5 Conclusions
- •References
- •53.1 Introduction
- •53.2 Hyaluronic Acid Gel Filler
- •53.3 Patient Marking and Preparation
- •53.4 The Injection
- •53.5 Complications
- •53.6 Discussion
- •53.7 Conclusions
- •References
- •54: Combined Technique in Otoplasty
- •54.1 Introduction
- •54.2 Technique
- •54.3 Complications
- •54.4 Discussion
- •54.5 Conclusions
- •References
- •55: Rhinoplasty
- •55.1 Introduction
- •55.2 Types of Nasal Deformity
- •55.3 Preoperative Analysis
- •55.4 Surgical Techniques
- •55.4.1 Incisions in Rhinoplasty
- •55.4.2 Osteotomies in Rhinoplasty
- •55.5 Complications
- •55.5.1 Intrasurgical Complications
- •55.5.2 Immediate Postoperative Complications
- •55.5.3 Early Postoperative Complications
- •55.5.4 Late Postoperative Complications
- •55.6 Conclusions
- •References
- •56.1 Introduction
- •56.2 Biochemistry
- •56.3 Storage
- •56.4 Mechanism of Action
- •56.5 Duration of Action
- •56.6 Clinical Uses
- •56.6.1 FDA-Approved Uses
- •56.6.2 Aesthetic Off-Label Uses
- •56.8 Nonsurgical Rhinoplasty
- •56.8.1 Initial Consult
- •56.8.2 Physical Examination
- •56.8.3 Nasal Anatomy
- •56.8.4 Anesthesia and Prophylaxis
- •56.8.5 Needles
- •56.8.6 Injection Technique
- •56.8.7 Dosage
- •56.8.8 Postinjection Care
- •56.8.9 Patient Satisfaction
- •56.9.1 Asian
- •56.9.2 African-American
- •56.9.3 Hispanic
- •56.9.4 Arabic (Middle Eastern)
- •56.9.5 Aging
- •56.9.6 Revision Rhinoplasty
- •56.10 Discussion
- •56.11 Conclusions
- •References
- •57: Lip Enhancement: Personal Technique
- •57.1 Introduction
- •57.2 Anatomical Basics of the Human Lip
- •57.3 Injectable Materials
- •57.4 Technique
- •57.5 Postoperative Instructions
- •57.6 Complications
- •57.7 Discussion
- •References
- •58.1 Introduction
- •58.2 Advantages
- •58.3 Mechanism of Action
- •58.4 The Tumescent Technique
- •58.5 Indications
- •58.6 Contraindications
- •58.7 Technique
- •58.8 Complications
- •58.9 Special Considerations
- •58.9.1 Submandibular Gland Exposure
- •58.9.2 Platysmal Band Exposure
- •58.9.3 Thyroid Thickness or Band
- •58.9.4 Receding Chin
- •References
- •59: Neck Lifting Variations
- •59.1 Introduction
- •59.2 Pathophysiology of the Aging Neck
- •59.2.1 Aging Skin
- •59.2.2 Aging Soft Tissue
- •59.2.3 Aging Facial Skeleton
- •59.3 Other Factors
- •59.4 Evaluation of the Aging Neck
- •59.4.2 Physical Findings
- •59.5 Jowl/Mandibular Evaluation
- •59.6 Submental/Neck Evaluation
- •59.7 Surgical Technique Selection
- •59.7.1 Nonsurgical Intervention
- •59.7.2 Botulinum Toxin A
- •59.7.3 Skin Tightening Procedures
- •59.7.4 Intradermal Fillers
- •59.7.5 Laser Resurfacing
- •59.8 Surgical Treatment
- •59.8.1 Liposculpting
- •59.8.2 Platysmaplasty
- •59.8.3 Rhytidoplasty
- •59.9 Special Neck Lifting
- •59.9.1 Vertical Neck Lift
- •59.9.2 Horizontal Neck Lift
- •59.10 Clinical Pearls and Pitfalls
- •References
- •60.1 Introduction
- •60.2 Technique
- •60.3 Instructions
- •60.3.1 Day of Treatment
- •60.3.2 Second Day: Micropore Tape Mask Removal and Application of Subgalatic Mask
- •60.3.3 Eighth Day: Bismuth Subgalatic Mask Removal
- •60.4 Patient Instructions
- •60.4.1 Shopping List
- •60.4.2 Night Before Procedure
- •60.4.3 The Procedure (Day 1)
- •60.4.6 Days Four (4) to Seven (7)
- •60.4.7 Mask Removal on Day Eight (8)
- •60.5 Remember
- •60.6 Complications
- •60.7 Discussion
- •60.8 Conclusions
- •61.1 Applications of Permanent Cosmetics
- •61.2 Preprocedure Preparation
- •61.3 Pigment Blends
- •61.4 Eyebrows
- •61.5 Lips
- •61.6 Postprocedure Considerations
- •61.6.1 Longevity
- •61.6.2 Risks
- •61.7 Conclusions
- •Recommended Reading
- •62.1 Introduction
- •62.4 Mechanism of Action/Histology
- •62.5 Technique
- •62.6 Longevity
- •62.7 Complications
- •62.8 Conclusions
- •References
- •63.2 Prevalence
- •63.3 Clinical Features
- •63.3.1 Morphological Changes
- •63.3.2 Metabolic Changes
- •63.3.3 Pathogenesis
- •63.3.4 Protease Inhibitors
- •63.4 HIV Infection
- •63.5 Nutritional Status, Age, and Adiposity
- •63.6 Female Sex
- •63.7 Cytokines
- •63.8 Management
- •63.8.1 Nonsurgical Treatment of HIV Facial Lipoatrophy
- •63.9 Autologous Fat Transfer
- •63.9.1 History of Autologous Fat Transfer
- •63.10 Theories of Fat Graft Survival
- •63.11 Histological Evaluation of Transplanted Fat
- •63.12 Technique
- •63.13 Surgical Technique
- •63.13.1 Anaesthesia of the Donor Site
- •63.13.2 Choice of Donor Site
- •63.13.3 Harvesting Method
- •63.15 Placement
- •63.16 Post-operative Care
- •63.17 Complications
- •63.18 Discussion
- •63.19 Conclusions
- •References
- •64.1 Introduction
- •64.2 Comparative Studies
- •References
- •65.1 Introduction
- •65.2.1 Duty
- •65.2.2 Breach of Duty (Negligence)
- •65.2.3 Causation
- •65.2.4 Damages
- •65.3 Avoiding Lawsuits
- •65.4 What to Do When a Lawsuit Is Threatened or Filed
- •Index
50 |
G.D. Bennett |
6.3 Ancillary Personnel
The facility or office must be staffed by individuals with the training and experience required to assist in the care of the patient [9, 10]. Use of qualified and experienced operating room personnel has been shown to improve operating room efficiency and reduce surgical morbidity [11, 12]. All personnel assisting in the operating room and recovery area should maintain Basic Life Support (BLS) Certification [13]. At least one health care provider in the facility must be certified to deliver advanced cardiac life support (ACLS) when anesthesia is administered [14]. The surgeon may prefer to enlist the assistance of an anesthesiologist or CRNA to provide intraoperative anesthesia and monitoring. If the surgeon elects to administer parenteral sedative or analgesic medication without the assistance of an anesthesiologist or CNRA, then a second licensed health care provider should be available to deliver the medications to the patient and monitor the patient throughout the perioperative period [15]. The use of untrained, unlicensed personnel to administer medication to the patient and monitor the patient is associated with an increased risk of anesthesia-related complications to the patient. The nurse who has been assigned to monitor the patient during the administration of sedative and analgesic medication should not be required to double as a circulating or scrub nurse [16]. Preferably, the surgeon who chooses to administer anesthesia should also be ACLS Certified.
6.4 Preoperative Evaluation
Despite the development of minimally invasive nonsurgical and surgical procedures, the importance of the preoperative anesthesia evaluation should not be minimized. An old adage within many anesthesia training programs is that while there may be minor surgical procedures, there is no such thing as a minor anesthetic. If the surgeon chooses to administer the anesthesia then he/she assumes the full responsibility of the preoperative assessment. Even if an anesthesiologist or CRNA is to be involved on the day of surgery, a carefully performed preoperative evaluation by the surgeon is instrumental in reducing potential delays or cancellations of surgery and improving the overall perioperative risk to the patient [17].
Acomprehensive preoperative patient questionnaire is an invaluable tool to begin the initial assessment. Information contained in the history may determine the diagnosis of the medical condition in nearly 90% of patients [18]. Information requested by the questionnaire should include all current and prior medical conditions, prior surgeries and types of anesthesia received, adverse outcomes to previous anesthetics or other medications, eating disorders, prior or current use of antiobesity medications, current use of homeopathic or herbal supplements, and prior family history of severe reactions to anesthetics such as malignant hyperthermia. A complete review of systems, including questions about the presence of chest pain, shortness of breath, loss of consciousness, spontaneous bleeding or bruising, spontaneous weight loss, fever, or fatigue is crucial in identifying previously undiagnosed, untreated medical conditions, which could impact the outcome of anesthesia and surgery. Obtaining a family history of sudden, unsuspected illness or death is also important in identifying patients with potentially undiagnosed medical conditions.
Aroutine physical examination may alert the surgeon to certain medical conditions such as undiagnosed or inadequately treated hypertension, cardiac arrhythmias, cardiac failure, or bronchial asthma, which could result in increased risk to the patient during the perioperative period. Preliminary assessment of the head and neck anatomy may be useful to predict possible challenges in the event of an endotracheal intubation even if general anesthesia is not planned. Preoperative history and physical examination has been shown to be superior to laboratory analysis in determining the clinical course of anesthesia and surgery [19–23].
For patients with complicated, unstable, or previously unrecognized medical conditions, a consultation by the appropriate medical specialist is indicated to determine if the patient’s medical conditional is optimally managed, if the medical condition may cause a significant increased in the perioperative risk to the patient, and to assist with the perioperative medical management of the patient if required. Additional preoperative testing may be considered medically necessary by the consultant.
Guidelines for the judicious use of preoperative laboratory screening tests for healthy patients not taking medications are presented in Table 6.1. Additional
6 Anesthesia for Minimally Invasive Cosmetic Surgery of the Head and Neck |
51 |
preoperative tests, noted in Table 6.2, may be indicated for patients with prior medical conditions or risk factors for anesthesia and surgery.
Excessive or indiscriminately ordered preoperative laboratory testing for healthy patients not taking
Table 6.1 Guidelines for preoperative testing in healthy patients (ASA 1-11)
Age |
Test |
12–40a |
CBC |
40–60 |
CBC, EKG |
Greater than 60 |
CBC, BUN, glucose, ECG, CXR |
|
|
aPregnancy test for potentially childbearing females suggested Source: Adapted from Roizen et al. [24]
Table 6.2 Common indications for additional risk-specific testing
Electrocardiogram
History: Coronary artery disease, congestive heart failure, prior myocardial infarction, hypertension, hyperthyroidism, hypothyroidism, obesity, compulsive eating disorders, deep venous thrombosis, pulmonary embolism, smoking, chemotherapeutic agents, chemical dependency, chronic liver disease.
Symptoms: Chest pain, shortness of breath, dizziness
Signs: Abnormal heart rate or rhythm, hypertension, cyanosis, peripheral edema, wheezing, rales, rhonchi
Chest X-ray
History: Bronchial asthma, congestive heart failure, chronic obstructive pulmonary disease, and pulmonary embolism
Symptoms: Chest pain, shortness of breath, wheezing, unexplained weight loss, and hemoptysis
Signs: Cyanosis, wheezes, rales, rhonchi, decreased breath sounds, peripheral edema, abnormal heart rate or rhythm
Electrolytes, glucose, liver function tests, BUN, creatinine
History: Diabetes mellitus, chronic renal failure, chronic liver disease, adrenal insufficiency, hypothyroidism, hyperthyroidism, diuretic use, compulsive eating disorders, diarrhea
Symptoms: Dizziness, generalized fatigue or weakness
Signs: Abnormal heart rate or rhythm, peripheral edema, jaundice
Urinalysis
History: Diabetes mellitus, chronic renal disease, and recent urinary tract infection
Symptoms: Dysuria, urgency, frequency, and bloody urine
Source: Adapted from Roizen et al. [25]
medications has limited value in predicting surgical or anesthesia-related morbidity and mortality [26–30].
6.4.1 Preoperative Risk Assessment
One critical goal of the preoperative evaluation is the determination of a patient’s overall level of risk related to the administration of anesthesia. By first establishing a patient’s level of risk, strategies to reduce the patient’s exposure may be considered. Compelling evidence suggests that certain coexisting medical conditions significantly increase the risk for perioperative morbidity and mortality [15, 31]. The risk classification system developed by the ASA in 1984 (Table 6.3) [32] has become the most widely accepted method of preoperative risk assessment. The value of the ASA system in predicting which patients are at higher risk for morbidity [33] and mortality [34–36] has been confirmed by numerous studies. Goldman and Caldera [37] established a risk assessment index based on cardiac disease, which has also been demonstrated to be effective in predicting perioperative mortality [38, 39]. Physicians should incorporate one of the acceptable risk classification systems as an integral part of the preoperative evaluation.
The type of surgery plays a key role in the overall risk of morbidity and mortality to the patient. The consensus of multiple studies confirms that more invasive surgeries, surgeries with multiple combined procedures, surgeries of prolonged duration, and surgeries with significant blood loss increases the risk of
Table 6.3 The American Society of Anesthesiologists’ physical status classification
ASA Class I |
A healthy patient without systemic medical |
|
or psychiatric illness |
ASA Class II |
A patient with mild, treated and stable |
|
systemic medical or psychiatric illness |
ASA Class III |
A patient with severe systemic disease that |
|
is not considered incapacitating |
ASA Class IV |
A patient with severe systemic, incapacitat- |
|
ing and life-threatening disease not |
|
necessarily correctable by medication or |
|
surgery |
ASA Class V |
A patient considered moribund and not |
|
expected to live more than 24 h |
52 |
|
|
|
|
|
|
|
|
G.D. Bennett |
||
perioperative complications [40–44]. However, even |
myocardial infarction [49–51]. More recent studies |
||||||||||
with more minor procedures involving sedation or |
suggest that if patients are monitored postoperatively |
||||||||||
anesthesia, the physician should not neglect the preop- |
in the hospital cardiac care unit with invasive hemody- |
||||||||||
erative evaluation and risk assessment. |
|
namic monitoring, the rate of perioperative reinfarc- |
|||||||||
|
|
|
|
tion and death is reduced [52, 53]. At this time, |
|||||||
|
|
|
|
postponing all but the most minor elective cosmetic |
|||||||
|
|
|
|
surgeries for at least 6 months after a myocardial |
|||||||
6.4.2 Anesthesia and Patients |
|
infarction remains the most prudent decision. |
|
||||||||
|
with Preexisting Disease |
|
The cardiac risk index established by Goldman |
||||||||
|
|
|
|
et al. [37] has proven extremely helpful in identifying |
|||||||
Surgeons who perform outpatient surgery, especially |
patients with intermediate risk for perioperative car- |
||||||||||
diac complication [38]. Patients should be referred to |
|||||||||||
office-based surgery, and particularly those surgeons |
|||||||||||
a cardiologist for preoperative evaluation if the risk |
|||||||||||
who choose to administer sedative or analgesic medi- |
|||||||||||
index score is greater than 13. Dipyridamole thallium |
|||||||||||
cation, must appreciate how preexisting medical con- |
|||||||||||
scanning and dobutamine or adenosine stress echocar- |
|||||||||||
ditions |
may increase the risk |
of anesthesia |
in the |
||||||||
diography can predict potential perioperative cardiac |
|||||||||||
surgical |
patient. Furthermore, |
the surgeon |
should |
||||||||
complication [54]. A |
simple |
but reliable screening |
|||||||||
maintain a reasonable understanding of the basic eval- |
|||||||||||
tool to |
evaluate |
the |
patient’s |
cardiac status is |
the |
||||||
uation and treatment of these medical conditions. The |
|||||||||||
patient’s |
exercise |
tolerance. The |
patient’s ability |
to |
|||||||
following sections contain an introduction to consider- |
|||||||||||
increase |
the heart rate of 85% |
of the age-adjusted |
|||||||||
ations of medical conditions which may have a signifi- |
|||||||||||
maximal rate reliably predicts perioperative cardiac |
|||||||||||
cant impact on a patient during the course of anesthesia |
|||||||||||
morbidity [55]. |
|
|
|
|
|
||||||
and surgery. |
|
|
|
|
|
|
|
||||
|
|
No one anesthetic technique or medication has ever |
|||||||||
|
|
|
|
||||||||
|
|
|
|
emerged as the preferential method to reduce the inci- |
|||||||
|
|
|
|
dence of perioperative complication in patients with |
|||||||
6.4.3 Cardiac Disease |
|
|
cardiac disease [56, 57]. Most anesthesiologists agree |
||||||||
|
|
that perioperative cardiac complications can be reduced |
|||||||||
|
|
|
|
||||||||
|
|
|
|
through scrupulous patient monitoring and avoiding |
|||||||
The leading cause of perioperative anesthetic and sur- |
respiratory and hemodynamic fluctuations. |
|
|||||||||
gical mortality is complications related to cardiac dis- |
|
|
|
|
|
|
|
||||
ease, including myocardial infarction and congestive |
|
|
|
|
|
|
|
||||
heart failure [45, 46]. Fortunately, a careful preopera- |
6.4.4 Obesity |
|
|
|
|
|
|||||
tive history and physical can identify most patients |
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|||||
with preoperative heart disease [23]. When assessing |
|
|
|
|
|
|
|
||||
patients who are apparently asymptomatic for heart |
With over 55% of the population of the USA afflicted, |
||||||||||
disease, but have risk factors for heart disease such as |
obesity has attained epidemic proportions [58]. In fact, |
||||||||||
smoking, hypertension, diabetes mellitus, obesity, |
obesity has emerged as one of the most prevalent health |
||||||||||
hyperlipidemia, or a family history of severe heart dis- |
concerns in the developing world. Assuredly, physi- |
||||||||||
ease, the prudent physician should be aware that 80% |
cians who work with patients undergoing cosmetic |
||||||||||
of all episodes of myocardial ischemia are silent [47, |
surgery will routinely encounter patients with this pre- |
||||||||||
48]. Patients with known cardiac disease must be eval- |
existing medical condition. These physicians must be |
||||||||||
uated by the internist or the cardiologist to ensure the |
aware that obesity is associated with other risk factors |
||||||||||
medical condition is optimally managed. Anesthesia |
such as diabetes mellitus, heart disease, hypertension, |
||||||||||
and all except the most minor surgical procedures on |
sleep apnea, and occult liver disease [59]. A thorough |
||||||||||
patients with significant heart disease should preferen- |
preoperative evaluation must rule out these added risk |
||||||||||
tially be performed in a hospital setting. |
|
factors prior to elective cosmetic surgery. |
|
||||||||
Most studies have demonstrated a dramatically |
The body mass index (BMI), which is determined |
||||||||||
greater risk of reinfarction and death in patients under- |
by weight (kg) divided by height (m) squared, has |
||||||||||
going surgery within 6 months after sustaining a |
become the standard method of quantifying the level |
||||||||||
6 Anesthesia for Minimally Invasive Cosmetic Surgery of the Head and Neck |
53 |
of obesity. Patients with a BMI over 30 are considered obese, while a BMI over 35 indicates morbid obesity [60]. Morbidly obese patients (BMI greater than 35) undergoing major surgery or any surgery where a general anesthetic is planned, should preferentially be referred to a hospital with health-care providers experienced with the management of this high-risk group.
Airway control in morbidly obese patients may be particularly challenging due to anatomical abnormalities of the airway [61]. The combination of higher gastric volume, lower gastric pH, and increased frequency of esophageal reflux elevates the risk of dreaded pulmonary aspiration [62]. The morbidly obese patient may have severe restriction in pulmonary function [63], which is further compromised in the supine position [64]. Pulmonary function may dangerously deteriorate when heavy sedation or general anesthesia is administered to the morbidly obese patient [65]. Hypoxemia may develop precipitously in this patient population while receiving heavy sedation or general anesthesia anytime in the perioperative period. Respiratory impairment may persist for up to 4 days after surgery or anesthesia [66].
Premedication with metaclopramide, or other dopamine receptor antagonist, and ranitidine, or similar histamine type-2 receptor antagonist, should be administered the evening prior to and on the morning of surgery to reduce the risk of pulmonary aspiration pneumonitis [67]. Because of the increased risk of deep venous thrombosis (DVT) [68] and pulmonary embolism (PE) [69], prophylactic measures such as lower extremity pneumatic compression devices and early ambulation should be used.
Fatal cardiac arrhythmias, sudden congestive heart failure, and intractable hypotension has developed in patients receiving anesthesia who have previously taken appetite suppressant medications such as aminorex fumarate, dexfenfluramine (Redux), fenfluramine (Pondimin), and phentermine (Ionam, Adipex-P, Fastin, Oby-Cap, Obenix, Oby-trim, or Zantryl). Some authors advocate a cardiac evaluation with an echocardiogram to rule out valvular disease associated with these medications, and continuous wave Doppler imaging with color-flow examination for any patient who has previously taken any antiobesity medications. Sustained hypotension may not respond to ephedrine, a popular vasopressor. Phenylephrine is the treatment of choice for hypotension in this patient population [70].
6.4.5 Hypertension
Perioperative mortality is significantly increased in patients with untreated or poorly controlled hypertension [71, 72]. Satisfactory control of hypertension reduces the risk of mortality due to complications related to cardiovascular and cerebral vascular disease [73–75]. Most authors concur that preoperative stabilization of hypertension reduces perioperative cardiovascular complications such as ischemia [76–78]. Patients with undiagnosed or poorly controlled hypertension can easily be identified in the preoperative examination and referred to the family physician or internist for evaluation and treatment. Attributing severe hypertension to the patient’s preoperative level of anxiety can be a deadly assumption. Considering that many effective medications are available for the treatment of hypertension, there is little defense for the physician who proceeds with surgery in a patient with uncontrolled hypertension.
Previously prescribed antihypertensive medications should be continued up to and including the morning of surgery. Abrupt withdrawal from these medications may result in dangerous rebound hypertension [79]. The only exception are the class of medications known as angiotensin-converting enzyme (ACE) inhibitors, which have been associated with hypotension during the induction of general anesthesia [80].
While mild to moderate perioperative hypertension may be a response to anxiety, an inadequate level of anesthesia, or poor pain control, these cases of hypertension are usually accompanied by other signs such as verbal complaints of pain during local anesthesia, patient movement during general anesthesia, tachycardia, or tachypnea. If the pain treatment, anxiolytics, and depth of anesthesia have been deemed appropriate, then initiating treatment of the blood pressure is indicated.
Beta-adrenergic receptor blocking agents, such as propranolol, judiciously administered intravenously in doses of 0.5 mg at 10-min intervals, is especially effective in treating perioperative hypertension, which is accompanied by tachycardia. Even small doses of beta-adrenergic blocking agents can reduce the incidence of cardiac ischemia [78]. Labetalol, an antihypertensive medication with combined alpha-adrenergic and beta-adrenergic receptor blocking properties, administered in 10 mg doses every 10 min, is also a safe and effective alternative for treating both hypertension and tachycardia [81].
